Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
7
TCNNF Quote, Financials, Valuation and Earnings
Last price:
$4.82
Seasonality move
:
23.27%
Day range:
$4.70 - $5.11
52-week range:
$4.44 - $14.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.78x
P/B ratio:
0.70x
Volume:
334.5K
Avg. volume:
687.3K
1-year change:
-2.23%
Market cap:
$911.9M
Revenue:
$1.1B
EPS (TTM):
-$0.73
Analysts' Opinion
-
Consensus RatingTrulieve Cannabis has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Trulieve Cannabis has an estimated upside of 351.59% from its current price of $4.82.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $4.82.
Fair Value
-
According to the consensus of 0 analysts, Trulieve Cannabis has 351.59% upside to fair value with a price target of -- per share.
TCNNF vs. S&P 500
-
Over the past 5 trading days, Trulieve Cannabis has overperformed the S&P 500 by 2.03% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Trulieve Cannabis does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Trulieve Cannabis has grown year-over-year revenues for 3 quarters straight. In the most recent quarter Trulieve Cannabis reported revenues of $284.3M.
Earnings Growth
-
Trulieve Cannabis earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Trulieve Cannabis reported earnings per share of -$0.33.
Enterprise value:
1.1B
EV / Invested capital:
0.60x
Price / LTM sales:
0.78x
EV / EBIT:
8.07x
EV / Revenue:
0.91x
PEG ratio (5yr expected):
-0.05x
EV / Free cash flow:
4.20x
Price / Operating cash flow:
3.58x
Enterprise value / EBITDA:
3.46x
Gross Profit (TTM):
$682.6M
Return On Assets:
-4.58%
Net Income Margin (TTM):
-10.98%
Return On Equity:
-9.3%
Return On Invested Capital:
-6.82%
Operating Margin:
-1.29%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $1.2B | $1.1B | $1.2B | $275.2M | $284.3M | |
| Gross Profit | $665.4M | $591.9M | $682.6M | $142.9M | $173.3M | |
| Operating Income | $113.8M | $66.9M | $122.4M | $22.1M | -$3.7M | |
| EBITDA | $218.2M | -$45.1M | $309.4M | $78.6M | $49.2M | |
| Diluted EPS | -$1.47 | -$3.05 | -$0.73 | -$0.14 | -$0.33 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $446.7M | $385.7M | $492.6M | $486.7M | $603M | |
| Total Assets | $786.2M | $1.3B | $3.3B | $2.8B | $2.9B | |
| Current Liabilities | $95.1M | $94.5M | $150.3M | $251.8M | $136.7M | |
| Total Liabilities | $381.6M | $453.4M | $1.3B | $1.3B | $1.6B | |
| Total Equity | $404.6M | $822.6M | $2B | $1.4B | $1.3B | |
| Total Debt | $134.5M | $137.5M | $553.1M | $591.2M | $480.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$94.1M | $125.4M | $372.3M | $93.4M | $30.3M | |
| Cash From Investing | -$156.5M | -$66.4M | -$190.6M | -$5M | -$131.5M | |
| Cash From Financing | $151.8M | $25.3M | -$142.1M | -$51.3M | -$16.4M | |
| Free Cash Flow | -$353M | $45.7M | $255.2M | $84.6M | -$19.9M | |
TCNNF
Sector
Market Cap
$911.9M
$44.6M
Price % of 52-Week High
33.24%
45.71%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.68%
1-Year Price Total Return
-2.23%
-29.09%
Beta (5-Year)
1.397
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$4.77
200-day SMA
Sell
Level
$9.98
Bollinger Bands (100)
Sell
Level
6.66 - 12
Chaikin Money Flow
Sell
Level
-32.8M
20-day SMA
Sell
Level
$5.35
Relative Strength Index (RSI14)
Sell
Level
33.74
ADX Line
Buy
Level
7.56
Williams %R
Neutral
Level
-75.641
50-day SMA
Sell
Level
$8.17
MACD (12, 26)
Sell
Level
-0.86
25-day Aroon Oscillator
Sell
Level
-84
On Balance Volume
Sell
Level
-43.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.44)
Sell
CA Score
(Annual)
Level (-0.4091)
Buy
Beneish M-Score
(Annual)
Level (-3.4712)
Buy
Momentum Score
Level (10)
Buy
Ohlson Score
Level (0.2686)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Trulieve Cannabis Corp is a vertically integrated seed to sale and fully licensed medical marijuana company. It is mainly engaged in the cultivation, possession, use, sale, and distribution of medical cannabis.
Stock Forecast FAQ
In the current month, TCNNF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The TCNNF average analyst price target in the past 3 months is --.
-
Where Will Trulieve Cannabis Stock Be In 1 Year?
According to analysts, the consensus estimate is that Trulieve Cannabis share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Trulieve Cannabis?
Analysts are divided on their view about Trulieve Cannabis share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Trulieve Cannabis is a Sell and believe this share price will drop from its current level to --.
-
What Is Trulieve Cannabis's Price Target?
The price target for Trulieve Cannabis over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is TCNNF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Trulieve Cannabis is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of TCNNF?
You can purchase shares of Trulieve Cannabis via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Trulieve Cannabis shares.
-
What Is The Trulieve Cannabis Share Price Today?
Trulieve Cannabis was last trading at $4.82 per share. This represents the most recent stock quote for Trulieve Cannabis. Yesterday, Trulieve Cannabis closed at $4.82 per share.
-
How To Buy Trulieve Cannabis Stock Online?
In order to purchase Trulieve Cannabis stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
